Yujiro S. Hata - 11 Mar 2026 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Director
Signature
/s/ Matthew Kowalsky as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
11 Mar 2026
Net transactions value
$0
Form type
4
Filing time
13 Mar 2026, 16:17:04 UTC
Previous filing
02 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hata Yujiro S Director C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN /s/ Matthew Kowalsky as attorney-in-fact 13 Mar 2026 0001649119

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Award +20,000 $0.000000* 20,000 11 Mar 2026 Common Stock 20,000 $14.17 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.